Disclosures for "Exploring Endothelial Pathway Modulation as a Novel Therapeutic Strategy in Alzheimer Disease"
-
Dr. Okar has nothing to disclose.
-
Dr. Qaqish has nothing to disclose.
-
The institution of Dr. Murin has received research support from American Academy of Neurology.
-
Dr. Polhemus has nothing to disclose.
-
Mr. Perez-Magnelli has nothing to disclose.
-
Dr. Tarawneh has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Academy of Neurology. Dr. Tarawneh has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for SAGE Publishing. The institution of Dr. Tarawneh has received research support from NIH-R21AG067755 (Ohio State University). The institution of Dr. Tarawneh has received research support from NIH-RF1AG083744 (University of New Mexico). The institution of Dr. Tarawneh has received research support from NIH-5P30GM122734-Phase III COBRE (University of New Mexico). The institution of Dr. Tarawneh has received research support from NIH-CTSA (R01AG062624). Dr. Tarawneh has received personal compensation in the range of $500-$4,999 for serving as a Reviewer on several Study Sections with NIH. Dr. Tarawneh has a non-compensated relationship as a Editorial Board Member with American Academy of Neurology-Neurology journal that is relevant to AAN interests or activities.